Further analysis revealed that the combination treatment increased the proportion of PD-1+CD8+ T cells in the peripheral blood, when compared to either anti-CD47 or anti-PD-L1 alone in both Panc02 and MPC-83 tumor-bearing mouse models (Fig. 7a, d). Here, CD47 is linked to neoplasm.